Multicavity [Pd(L)] metallosupramolecular cages based on long backboned ligands are an attractive approach to increasing molecular size without loss of the binding specificity conferred by small cavity [Pd(L)] assemblies. We herein report the synthesis of two double cavity polypyridyl [Pd(L)] cages that bind cisplatin [Pt(NH)Cl] within their internal cavities and interact with triflate (TfO) on their exohedral faces. We also report the first example of a triple cavity [Pd(L)] cage. This cage differs in that the central cavity is phenyl-linked rather than having the pyridyl core as in the peripheral cavities. The difference in cavity character results in selective guest binding of cisplatin in the peripheral cavities, with triflate binding within the central cavity and on the exohedral faces of the peripheral palladium(II) ions. All the cavities could be simultaneously filled by introducing both cisplatin and triflate concurrently, providing the first example of a discrete metallosupramolecular architecture with segregated guest binding in different designed internal cavities. The ligands and cages were characterized by NMR spectroscopy, mass spectrometry, elemental analysis, and, in one case, X-ray crystallography.

Metallosupramolecular architectures are beginning to be exploited for a range of applications including drug delivery, catalysis, molecular recognition, and sensing. For the most part these achievements have been made with high-symmetry metallosupramolecular architectures composed of just one type of ligand and metal ion. Recently, considerable efforts have been made to generate metallosupramolecular architectures that are made up of multiple different ligands and/or metals ions in order to obtain more complex systems with new properties. Herein we show that the addition of an electron-rich 2-amino-substituted tripyridyl ligand, 2,6-bis(pyridin-3-ylethynyl)pyridine (2A-tripy), to a solution of the [Pd2(tripy)4](4+) cage resulted in the clean generation of a heteroleptic [Pd2(tripy)2(2A-tripy)2](4+) architecture. The formation of the mixed-ligand cage [Pd2(tripy)2(2A-tripy)2](4+) was confirmed using (1)H NMR spectroscopy, diffusion-ordered spectroscopy, and rotating-frame nuclear Overhauser effect spectroscopy and high-resolution electrospray ionization mass spectrometry. Density functional theory calculations suggested the cis isomer was more stable that the trans isomer. Additionally, the calculations indicated that the heteroleptic palladium(II) cages are kinetically metastable intermediates rather than the thermodynamic product of the reaction. Competition experiments supported that finding and showed the cages are long-lived in solution at room temperature. Finally, it was shown that the addition of 2A-tripy to a range of preformed [Pd2(Ltripy)4](4+) cages cleanly generated the mixed-ligand systems. Three other systems displaying different exo and endo functionalities within the cage assembly were generated, suggesting that this method could be applied to synthesize a range of highly functionalized heteroleptic cis-[Pd2(La)2(Lb)2](4+) cages.

There is considerable interest in exploiting metallosupramolecular cages as drug delivery vectors. Recently, we developed a [Pd2L4](4+) cage capable of binding two molecules of cisplatin. Unfortunately, this first generation cage was rapidly decomposed by common biologically relevant nucleophiles. In an effort to improve the kinetic stability of these cage architectures here we report the synthesis of two amino substituted tripyridyl 2,6-bis(pyridin-3-ylethynyl)pyridine () ligands (with amino groups either in the 2-() or 3-() positions of the terminal pyridines) and their respective [Pd2()4](4+) cages. These systems have been characterised by (1)H, (13)C and DOSY NMR spectroscopies, high resolution electrospray mass spectrometry, elemental analysis and, in one case, by X-ray crystallography. It was established, using model palladium(ii) N-heterocyclic carbene (NHC) probe complexes, that the amino substituted compounds were stronger donor ligands than the parent system ( > > ). Competition experiments with a range of nucleophiles showed that these substitutions lead to more kinetically robust cage architectures, with [Pd2()4](4+) proving the most stable. Biological testing on the three ligands and cages against A549 and MDA-MB-231 cell lines showed that only [Pd2()4](4+) exhibited any appreciable cytotoxicity, with a modest IC50 of 36.4 ± 1.9 μM against the MDA-MB-231 cell line. Unfortunately, the increase in kinetic stability of the [Pd2()4](4+) cages was accompanied by loss of cisplatin-binding ability.

We report a simple, low-symmetry 2-(1-(pyridine-4-methyl)-1H-1,2,3-triazol-4-yl)pyridine ligand that has both monodentate and bidentate binding sites. With platinum(II) and/or palladium(II) ions, two examples of a new nona-nuclear metallo-assembly have been accessed. These complexes were characterized by NMR spectroscopy, electrospray mass spectrometry (ESI-MS), and in key cases, X-ray crystallography. The cages possess three clefts comprised of planar cationic panels. This structural feature enables the binding of planar aromatic guests such as anthracene. More interestingly, the heterometallic assembly was able to catalyze the light-induced [4+2] cycloaddition of anthracene with singlet oxygen.